RxDoctor Payments Data

Katherine Mazzola

Family · Winchester, VANPI 1396347738

Payments from drug & device makers

$1,182in general payments, 2019–2025

Across 48 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$235
  • Novartis$172
  • Otsuka America Pharmaceutical, Inc.$129
  • Ardelyx, Inc.$124
  • Mallinckrodt Hospital Products Inc.$80
  • ANI Pharmaceuticals, Inc.$65
  • plus $376 from 11 others

What the payments were for

  • Food & beverage$1,09593%
  • Education$877%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,182 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$8,259
Medicare patients
61
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol23$21,097
VeltassaPatiromer Calcium Sorbitex18$20,329
JardianceEmpagliflozin13$17,846
Cinacalcet Hcl43$11,432
Sevelamer Carbonate24$4,526
Calcitriol287$3,893
Midodrine Hcl32$1,717
Potassium Chloride58$1,556
Potassium Citrate ErPotassium Citrate24$1,514
Amlodipine Besylate261$1,479
Hydralazine Hcl113$1,433
Bumetanide27$1,271
Labetalol Hcl45$1,170
Furosemide235$1,143
Nifedipine ErNifedipine36$1,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$60$21,09723 claims
Boehringer IngelheimJardiance$16$17,84613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →